FY2026 Earnings Forecast for CRSP Issued By Chardan Capital

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Chardan Capital issued their FY2026 earnings per share estimates for CRISPR Therapeutics in a research report issued to clients and investors on Wednesday, May 7th. Chardan Capital analyst Y. Livshits anticipates that the company will earn ($3.97) per share for the year. Chardan Capital has a “Buy” rating and a $82.00 price target on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same quarter in the previous year, the company posted ($1.43) earnings per share. CRISPR Therapeutics’s quarterly revenue was up 71.6% compared to the same quarter last year.

A number of other brokerages also recently issued reports on CRSP. The Goldman Sachs Group reduced their price objective on CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating for the company in a research note on Thursday. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. Morgan Stanley lifted their price target on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a report on Friday, February 14th. Finally, HC Wainwright restated a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and an average target price of $73.12.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $35.62 on Friday. The firm has a market cap of $3.08 billion, a price-to-earnings ratio of -8.15 and a beta of 1.88. The firm has a 50-day moving average price of $38.15 and a two-hundred day moving average price of $42.77. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $67.88.

Institutional Trading of CRISPR Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. ARK Investment Management LLC raised its position in CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after purchasing an additional 1,474,439 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of CRISPR Therapeutics by 39.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after buying an additional 1,074,238 shares in the last quarter. Capital International Investors lifted its position in CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock worth $344,145,000 after buying an additional 816,789 shares during the last quarter. Baker BROS. Advisors LP lifted its position in CRISPR Therapeutics by 55.1% in the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company’s stock worth $51,483,000 after buying an additional 464,936 shares during the last quarter. Finally, Norges Bank purchased a new stake in CRISPR Therapeutics in the fourth quarter worth approximately $17,458,000. 69.20% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel James R. Kasinger sold 2,850 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the transaction, the general counsel now owns 77,530 shares in the company, valued at approximately $3,288,822.60. This trade represents a 3.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,381 shares of company stock worth $1,608,243 over the last ninety days. 4.30% of the stock is owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.